Adial Pharmaceuticals, Inc. Amortization of Debt Discount (Premium)
Adial Pharmaceuticals, Inc. (ADIL) reported Amortization of Debt Discount (Premium) of $352.67 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2020-03-20
- Adial Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2018-12-31 was $186.40K, a 314.96% increase year-over-year.
- Adial Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2018-09-30 was $105.28K, a 133.51% increase year-over-year.
- Adial Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2018-06-30 was $28.69K.
- Adial Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2018-03-31 was $32.30K.
- Adial Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2018 was $352.67K, a 244.87% increase from fiscal 2017.
- Adial Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2017 was $102.26K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $186.40K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $291.68K derived: sum of 2 quarters · filed 2020-03-20 | $320.37K derived: sum of 3 quarters · filed 2020-03-20 | $352.67K 10-K · filed 2020-03-20 |
| 2018-09-30 | $105.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $133.97K derived: sum of 2 quarters · filed 2019-11-14 | $166.28K 10-Q · filed 2019-11-14 | $211.19K derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $28.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $60.99K 10-Q · filed 2019-08-13 | $105.91K derived: sum of 3 quarters · filed 2019-08-13 | $151.00K derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $32.30K 10-Q · filed 2019-05-13 | $77.22K derived: sum of 2 quarters · filed 2019-05-13 | $122.31K derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | $44.92K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $90.01K derived: sum of 2 quarters · filed 2019-02-19 | $102.26K 10-K · filed 2019-02-19 | |
| 2017-09-30 | $45.09K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $57.34K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $12.26K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |